Qualigen Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0

LB filings
2025.11.14 22:18
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -4.68.

EBIT: As of FY2025 Q3, the actual value is USD -1.168 M.

Operational Metrics

  • Net Loss: For the three months ended September 30, 2025, the net loss was - $2,037,819, compared to - $1,794,060 for the same period in 2024. For the nine months ended September 30, 2025, the net loss was - $6,369,407, compared to - $5,403,368 for the same period in 2024.
  • General and Administrative Expenses: Increased to $1,891,108 for the three months ended September 30, 2025, from $1,145,152 in the same period in 2024. For the nine months ended September 30, 2025, expenses were $5,780,572, up from $3,186,575 in 2024.
  • Research and Development Expenses: Decreased to $105,576 for the three months ended September 30, 2025, from $123,429 in the same period in 2024. For the nine months ended September 30, 2025, expenses were $156,558, down from $1,242,101 in 2024.

Cash Flow

  • Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used was - $4,828,986, compared to - $4,057,980 for the same period in 2024.
  • Net Cash Used in Investing Activities: For the nine months ended September 30, 2025, net cash used was - $1,809,500, compared to - $900,000 for the same period in 2024.
  • Net Cash Provided by Financing Activities: For the nine months ended September 30, 2025, net cash provided was $44,241,044, compared to $4,944,329 for the same period in 2024.

Unique Metrics

  • Convertible Debt: As of September 30, 2025, the fair value of convertible debt was $339,736.
  • Warrant Liabilities: As of September 30, 2025, warrant liabilities were valued at $362,323.

Future Outlook and Strategy

  • Core Business Focus: The company plans to use up to $6.8 million of the net proceeds from recent funding to pay existing debt and fund existing business operations, with the balance used for establishing cryptocurrency treasury operations.
  • Non-Core Business: The company has slowed the development of its therapeutic products due to financial constraints and is implementing expense controls. Management is reviewing strategic plans to advance the therapeutics pipeline when properly funded.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.